Nektar announces initiation of first-in-human phase 1 clinical study of NKTR-255
Nektar Therapeutics announced initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. October 16, 2019